Bosh sahifa207940 • KRX
add
Samsung Biologics Co Ltd
Yopilish kursi
1 000 000,00 ₩
Kunlik diapazon
1 005 000,00 ₩ - 1 044 000,00 ₩
Yillik diapazon
721 000,00 ₩ - 1 113 000,00 ₩
Bozor kapitalizatsiyasi
72,03 trln KRW
Oʻrtacha hajm
71,47 ming
Narx/foyda
68,43
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,19 trln | 14,81% |
Joriy xarajat | 202,29 mlrd | 11,50% |
Sof foyda | 264,47 mlrd | 10,03% |
Sof foyda marjasi | 22,28 | -4,17% |
Har bir ulushga tushum | 3,72 ming | 10,07% |
EBITDA | 495,40 mlrd | 8,39% |
Amaldagi soliq stavkasi | 9,12% | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 988,11 mlrd | -45,63% |
Jami aktivlari | 16,03 trln | 0,87% |
Jami passivlari | 5,43 trln | -14,30% |
Umumiy kapital | 10,59 trln | — |
Tarqatilgan aksiyalar | 71,17 mln | — |
Narxi/balansdagi bahosi | 6,72 | — |
Aktivlardan daromad | 5,23% | — |
Kapitaldan daromad | 7,18% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 264,47 mlrd | 10,03% |
Operatsiyalardan naqd pul | 740,39 mlrd | 154,07% |
Sarmoyadan naqd pul | -437,12 mlrd | -17,41% |
Moliyadan naqd pul | -713,37 mlrd | -297,72% |
Naqd pulning sof oʻzgarishi | -433,28 mlrd | -69,49% |
Boʻsh pul | -12,12 mlrd | -237,42% |
Haqida
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Tashkil etilgan
2011
Xodimlar soni
4 744
